Boehringer Ingelheim and Eli Lilly’s Jardiance Approved by EC for Chronic Kidney Disease
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...
Eli Lilly
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis
The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...
XtalPi Partners with Eli Lilly for AI-Driven Drug Discovery Services
Sino-US artificial intelligence (AI) firm XtalPi Inc. has been enlisted by US-giant Eli Lilly &...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...
LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
Kelun Pharma’s Generic Jardiance Gains New Indication in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...
Eli Lilly Reports Q4 Financials with COVID-19 Impact and Market Performers
Eli Lilly & Co. (NYSE: LLY) reported its Q4 2022 financials, revealing a 9% year-on-year...
AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab
China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole...
Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China
The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...
GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...
Lavamed Secures USD 40M in Angel and Series A Financing Rounds
Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...